Medication info
EmpaMax M Extended Release Tablet 12.5/1000 mg (Empagliflozin, Metformin)

EmpaMax M Extended Release Tablet 12.5/1000 mg (Empagliflozin, Metformin)

Prescription medicationTabletOral
Ingredient · strength
Empagliflozin L-Proline›15.69mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Jonggeun Dang Co., Ltd.
Appearance
Pink oval extended-release film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202501901 · Approved 2025.07.24 · Insurance code 643310030

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medication for antidiabetic therapy should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25mg and metformin hydrochloride 2000 mg as extended-release formulation. To reduce gastrointestinal adverse reactions caused by metformin, take this medication once daily in the evening with a meal. Patients taking this medication as 10/1000 mg or 25/1000 mg extended-release tablets should take 1 tablet once daily. Patients taking this medication as 12.5/1000 mg or 12.5/750 mg extended-release tablets should take 2 tablets together once daily. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. To maintain its extended-release properties, swallow this medication whole; do not split, crush, grind, or chew it. This medication may not dissolve completely and may be excreted in the stool. For patients whose blood glucose is not adequately controlled with metformin alone or in combination with other medications such as insulin, the recommended initial total daily dose when taking this medication is empagliflozin 10 mg and the patient’s current metformin dose. If empagliflozin 10 mg is well tolerated but additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg. Patients switching from concomitant therapy with empagliflozin and metformin to this medication should receive their existing doses of empagliflozin and metformin. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted as appropriate. When this medication is co-administered with a sulfonylurea or insulin, reducing the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia. Because dose adjustment based on renal function may be necessary, renal function should be assessed before starting this medication and periodically during treatment. No dose adjustment of this medication is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2] who tolerate treatment well and have no other conditions that may increase the risk of lactic acidosis, this medication may be used by adjusting the dose of metformin hydrochloride as follows. The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this medication. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to below 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to below 45 ml/min/1.73m2, this medication should be discontinued immediately. In patients aged 75 years and older, renal function and the risk of volume depletion should be taken into consideration.

Ingredients

Manufacturer
Jonggeun Dang Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Blood glucose control issues in adult patients with type 2 diabetes
  • cardiovascular diseases
View approved original text

This medication is used as a combination of Empagliflozin and Metformin to help control blood glucose levels in adult patients with type 2 diabetes, supplementing dietary and exercise therapy. It is particularly administered to patients whose blood glucose is not adequately controlled, and caution is required in patients with cardiovascular diseases according to this information. This medication is effective in managing blood glucose and is used in diabetes treatment.

How to take

Adult dose

The dose of this medication for antidiabetic therapy should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25mg and metformin hydrochloride 2000 mg as extended-release formulation. To reduce gastrointestinal adverse reactions caused by metformin, take this medication once daily in the evening with a meal. Patients taking this medication as 10/1000 mg or 25/1000 mg extended-release tablets should take 1 tablet once daily. Patients taking this medication as 12.5/1000 mg or 12.5/750 mg extended-release tablets should take 2 tablets together once daily. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. To maintain its extended-release properties, swallow this medication whole; do not split, crush, grind, or chew it. This medication may not dissolve completely and may be excreted in the stool. For patients whose blood glucose is not adequately controlled with metformin alone or in combination with other medications such as insulin, the recommended initial total daily dose when taking this medication is empagliflozin 10 mg and the patient’s current metformin dose. If empagliflozin 10 mg is well tolerated but additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg. Patients switching from concomitant therapy with empagliflozin and metformin to this medication should receive their existing doses of empagliflozin and metformin. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted as appropriate. When this medication is co-administered with a sulfonylurea or insulin, reducing the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia. Because dose adjustment based on renal function may be necessary, renal function should be assessed before starting this medication and periodically during treatment. No dose adjustment of this medication is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2] who tolerate treatment well and have no other conditions that may increase the risk of lactic acidosis, this medication may be used by adjusting the dose of metformin hydrochloride as follows. The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this medication. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to below 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to below 45 ml/min/1.73m2, this medication should be discontinued immediately. In patients aged 75 years and older, renal function and the risk of volume depletion should be taken into consideration.

Precautions

This medication helps lower blood glucose levels, with the active ingredients being Empagliflozin and Metformin. Rarely, serious metabolic disorders such as lactic acidosis may occur while taking this medication, so immediate consultation with a doctor is necessary if symptoms arise. There is a risk of hypoglycemia when used with other diabetes medications, so caution is needed. Do not use this medication in patients with moderate to severe renal impairment or acute kidney issues. Specific conditions such as severe infections, dehydration, heart failure, pre-and post-surgery, liver dysfunction, or in pregnant women should avoid or use this medication with caution. Regular kidney function tests should be conducted before and during treatment, particularly for elderly or patients with diminished kidney function who may require more frequent testing. As there is a risk of hypoglycemia with this medication, dose adjustment may be necessary when combined with drugs like insulin or sulfonylureas. Urinary tract infections or genital infections may occur during treatment, so rapid treatment is necessary if symptoms arise. Due to the risk of hypotension or dehydration from fluid loss, caution is needed when dehydration symptoms or instability in fluid status are present. This medication may lower vitamin B12 levels, so monitoring vitamin B12 levels is recommended with prolonged use. Alcohol consumption may increase the risk of lactic acidosis, so it is advisable to avoid drinking while taking this medication. It is not safe to use this medication in pregnant or potentially pregnant women or breastfeeding women. It is not recommended for children as safety and efficacy have not been established. In case of overdose, lactic acidosis or other serious side effects may occur, so immediate medical attention is required. The tablets should be swallowed whole and not crushed or chewed, and it is normal for the tablet coating to be excreted. During treatment, regular blood tests and physical examinations should be conducted to monitor for adverse reactions, and consultation with medical personnel is required if any unusual symptoms occur.

Side effects

  • Hypoglycemia
  • urinary tract infection
  • genital infection
  • increased urination
  • nausea
  • vomiting
  • diarrhea
  • abdominal pain
  • loss of appetite
  • constipation
Show 185 more
  • abnormal liver function test
  • hepatitis
  • altered taste
  • itching
  • rash
  • hives
  • erythema
  • angioedema
  • dysuria
  • interstitial nephritis
  • thirst
  • increased serum lipids
  • increased serum creatinine
  • decreased glomerular filtration rate
  • increased hematocrit
  • ketoacidosis
  • lactic acidosis
  • perineal necrosis
  • chronic gastritis
  • cerebral infarction
  • soft tissue infection
  • pneumonia
  • ankle fracture
  • lateral epicondylitis
  • facial bone fracture
  • musculoskeletal pain
  • myocardial infarction
  • pancreatic adenocarcinoma
  • constipation
  • gastritis
  • dry mouth
  • gastrointestinal disturbance
  • oral discomfort
  • salivary gland pain
  • headache
  • dizziness
  • weakness
  • chest discomfort
  • chest pain
  • nasopharyngitis
  • upper respiratory infection
  • bronchitis
  • chronic sinusitis
  • gastroenteritis
  • Helicobacter infection
  • periodontitis
  • appendiceal abscess
  • appendicitis
  • chronic tonsillitis
  • conjunctivitis
  • influenza
  • laryngitis
  • meningitis
  • chronic otitis media
  • paronychia
  • peritonsillar abscess
  • pulmonary tuberculosis
  • sepsis
  • subcutaneous abscess
  • tinea corporis
  • dental abscess
  • adnexal-ovarian abscess
  • vestibular neuritis
  • positional vertigo
  • sensory loss
  • sensory abnormality
  • amnesia
  • carotid artery stenosis
  • diabetic neuropathy
  • facial paralysis
  • intracranial aneurysm
  • memory abnormality
  • neuralgia
  • Parkinson's disease
  • polyneuropathy
  • sensory disability
  • drowsiness
  • CNS-origin dizziness
  • fatigue
  • peripheral edema
  • facial edema
  • peripheral swelling
  • fever
  • facial swelling
  • chills
  • strange sensations
  • edema
  • pain
  • pain at the puncture site
  • vascular stent stenosis
  • vascular stent thrombosis
  • weight loss
  • vulvar pruritus
  • benign prostatic hyperplasia
  • diabetic retinopathy
  • diplopia
  • hypertension
  • insomnia
  • anxiety
  • palpitations
  • tachycardia
  • atherosclerosis
  • deep vein thrombosis
  • diabetic vascular complications
  • peripheral artery occlusive disease
  • benign ovarian tumor
  • bladder cancer
  • gastric cancer
  • rectal cancer
  • thyroid cancer
  • uterine leiomyoma
  • acute cholecystitis
  • autoimmune hepatitis
  • cholelithiasis
  • hepatitis
  • otalgia
  • positional vertigo
  • dizziness
  • anemia
  • lymphadenopathy
  • hypothyroidism
  • thyroid nodule
  • diabetic foot
  • dermoid cyst
  • seborrheic dermatitis
  • atopic dermatitis
  • nummular eczema
  • heat rash
  • sebaceous gland hyperplasia
  • lumbar spinal stenosis
  • myalgia
  • limb pain
  • musculoskeletal chest pain
  • arthralgia
  • cervical stenosis
  • fibromyalgia
  • flank pain
  • fracture pain
  • muscular weakness
  • osteoarthritis
  • osteoporosis
  • rotator cuff syndrome
  • astigmatism
  • cataract
  • allergic conjunctivitis
  • blurred vision
  • corneal erosion
  • macular fibrosis
  • ocular discomfort
  • conjunctival hyperemia
  • pathological myopia
  • retinal detachment
  • retinal calcification
  • retinal vein occlusion
  • serous retinal detachment
  • eyelid edema
  • visual impairment
  • vitreous floaters
  • vitreous hemorrhage
  • nasal bleeding
  • asthma
  • exertional dyspnea
  • moist cough
  • allergic rhinitis
  • residual phlegm
  • cough
  • skin laceration
  • contusion
  • rib fracture
  • concussion
  • corneal abrasion
  • fall
  • hand fracture
  • iliotibial band syndrome
  • open globe injury
  • pelvic fracture
  • road traffic accident
  • splenic injury
  • sternum fracture
  • angina
  • Prinzmetal angina
  • coronary artery disease
  • myocardial infarction
  • unstable angina
  • sleep disorder

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly sealed container to prevent exposure to air and moisture. It is best to keep it at room temperature, between 1 and 30 degrees Celsius.

Appearance and packaging

Appearance

Pink oval extended-release film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.